Blog
RSS FeedPosted by Michael Wonder on 02 Dec 2021
PHARMAC in review (2021) - part 2
3 December 2021 - As expected, the interim report fails to address the elephant in the room. ...
Posted by Michael Wonder on 02 Dec 2021
PHARMAC review: 'Damning' interim report reveals 'fortress mentality', Māori, equity progress slow
2 December 2021 - An interim report of a major PHARMAC review has slated the Government drug buying agency over ...
Posted by Michael Wonder on 02 Dec 2021
PHARMAC welcomes interim report
2 December 2021 - PHARMAC accepts many of the observations made in the Interim Report and is already making changes ...
Posted by Michael Wonder on 01 Dec 2021
PHARMAC in review (2021)
2 December 2021 - Another dismal year in terms of the number of new medicines listed in the New Zealand ...
Posted by Michael Wonder on 30 Nov 2021
New Zealand Pharmaceutical Schedule - 1 December 2021
1 December 2021 - The December 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 25 Nov 2021
PHARMAC publishes minutes of August 2021 PTAC meeting
25 November 2021 - Another sparse meeting in terms of the number of new funding applications and funding applications for ...
Posted by Michael Wonder on 16 Nov 2021
PHARMAC widens access to adalimumab through transition to biosimilar
17 November 2021 - Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab ...
Posted by Michael Wonder on 07 Nov 2021
COVID-19: PHARMAC confident with growing stock of drugs to treat virus
7 November 2021 - PHARMAC is growing increasingly confident it is getting close to having enough of the drugs needed to ...
Posted by Michael Wonder on 06 Nov 2021
Novavax files COVID-19 vaccine for provisional approval in New Zealand
3 November 2021 - Submission to New Zealand's Medsafe marks the first protein-based COVID-19 vaccine submitted for authorisation to regulatory authorities ...
Posted by Michael Wonder on 06 Nov 2021
PHARMAC to fund baricitinib to treat moderate to severe cases of COVID-19
5 November 2021 - PHARMAC has purchased another new medicine, baricitinib, to treat moderate to severe cases of COVID-19, with 500 ...
Posted by Michael Wonder on 04 Nov 2021
A breakthrough treatment for cystic fibrosis needs funding now
3 November 2021 - Let’s just kick this off by addressing the elephant in the room. Trikafta, the breakthrough treatment ...
Posted by Michael Wonder on 03 Nov 2021
Government makes a mockery of PHARMAC review
3 November 2021 - “The ACT Party can today reveal the review into PHARMAC has been delayed by more than ...
Posted by Michael Wonder on 03 Nov 2021
Major PHARMAC review delayed nearly 3 months
3 November 2021 - A major review into Government drug buying agency PHARMAC has been delayed by nearly three months. ...
Posted by Michael Wonder on 31 Oct 2021
New Zealand Pharmaceutical Schedule - November 2021 update
1 November 2021 - The November 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2021
PHARMAC negotiates deal for a further COVID-19 treatment
31 October 2021 - PHARMAC has negotiated an agreement with Roche to purchase another COVID-19 treatment. ...